Clinical Ink’s Technology Deployed for Groundbreaking

Horsham, Pennsylvania, February 17, 2022 (GLOBE NEWSWIRE) –

Clinical Ink technology is deployed for groundbreaking cannabis research

J.The AMA publication demonstrates the validity of the assessment,
points to future research and applications in the real world

Horsham, Pennsylvania; February 17, 2021 (Business Wire) – Clinical Ink, a global clinical technology company, is pleased to announce the collaboration of our Director of Innovation Joan Severson on the recently published JAMA Psychiatry Driving Performance and Cannabis User Perception of Safety: A Randomized Clin Trial. Severson was part of a team led by Dr. Thomas Marcott, professor and co-director of the Center for Cannabis Medical Research at the University of California, San Diego.

As the legalization of cannabis in the United States expands, it is increasingly necessary to effectively measure its impact on the health, behavior, and society of users. Although breathalyzers exist to measure alcohol consumption and the ability to drive safely, equivalent tests for cannabis use have not been developed. In this test, the team deployed patented, digitized estimates from the BrainBaseline ™ Clinical Ink platform to help measure cannabis-related damage while driving.

Expanding our BrainBaseline assessments with other clinical trials (such as blood and urine tests) and linking changes in driving simulator performance to a standard field sobriety test, the study found that cannabis use resulted in “reduced driving” or worsening summary score for driving a car (CDS) for 4 hours after use, even though many participants themselves noted that they felt safe driving much earlier.

It is important to note that the researchers were unable to correlate the decrease in car driving of users with the amount of cannabis consumed or the concentration of THC in the blood. As a result, the study emphasizes the need for techniques such as digital cognitive measurements to effectively assess behavior or disorders due to cannabis use, including field testing.

These findings are a catalyst for expanding measures and exposure to cannabis – both negative and positive. The National Football League (NFL) recently announced $ 1 million in funding for the same team from the University of California, San Diego for a clinical trial that will use our mobile estimates to study the effects of cannabinoids on sports-related injuries, pain treatment and recovery.

“This study at JAMA, as well as the NFL award, further confirms BrainBaseline’s estimates from Clinical Ink as a multifunctional tool to better measure patients in real-time,” Severson said. “It also proves the growing need for advanced technology like ours to help expand clinical discoveries.”

About Clinical Ink

Clinical Ink, a global clinical technology company, offers confidence data from source to presentation. Our clinical technology and customizable direct data collection modules, eCOA, patient engagement, telecare, eConsent and instrumental data collection modules provide a suite of solutions for collecting and integrating electronic data from sites, clinicians, educators and patients into their sources. Clinical Ink’s therapeutic approach to research design and data collection – with special expertise in neurocognitive testing – provides more accurate scales for assessing cognitive and human factors including performance, behavior, movement and all real-world actions.

  • JAMA Clinical Ink Edition

  • Clinical Ink technology is deployed for groundbreaking cannabis research



Leave a Comment